Leerink Partnrs Comments on Merus' Q3 Earnings (NASDAQ:MRUS)

Key Points

• Leerink Partners has decreased its Q3 2025 earnings estimate for Merus to ($1.50) per share, down from a prior estimate of ($1.32), while the consensus estimate for the full year is ($3.85) per share.
• Merus recently reported Q2 earnings of ($2.23) per share, missing the consensus estimate, and achieved revenue of $8.83 million, below the expected $9.77 million.
• Analyst ratings for Merus include one sell, ten buy, and one strong buy, with a current consensus rating of "Moderate Buy" and an average target price of $88.50.

Merus N.V. (NASDAQ:MRUS - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2025 earnings estimates for shares of Merus in a research report issued to clients and investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($1.50) per share for the quarter, down from their prior estimate of ($1.32). The consensus estimate for Merus' current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus' Q4 2025 earnings at ($1.52) EPS, FY2025 earnings at ($6.63) EPS, FY2026 earnings at ($5.70) EPS and FY2027 earnings at ($5.85) EPS.

MRUS has been the topic of several other research reports. Wells Fargo & Company decreased their price target on shares of Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. BMO Capital Markets set a $110.00 target price on shares of Merus and gave the stock an "outperform" rating in a report on Friday, May 23rd. Wall Street Zen downgraded shares of Merus from a "hold" rating to a "sell" rating in a report on Sunday, July 20th. HC Wainwright upgraded shares of Merus to a "strong-buy" rating in a report on Wednesday, August 6th. Finally, Needham & Company LLC reduced their target price on shares of Merus from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $88.50.

Merus Stock Performance

MRUS opened at $64.00 on Monday. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $67.59. The firm's fifty day moving average is $58.10 and its 200 day moving average is $48.77. The stock has a market cap of $4.84 billion, a price-to-earnings ratio of -11.64 and a beta of 1.09.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The business had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.

Institutional Trading of Merus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRUS. GAMMA Investing LLC raised its stake in Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 603 shares during the period. CWM LLC raised its stake in Merus by 299.0% during the second quarter. CWM LLC now owns 802 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 601 shares during the period. State of Wyoming purchased a new position in Merus during the fourth quarter worth about $48,000. Wells Fargo & Company MN raised its stake in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in Merus during the fourth quarter worth about $60,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Insider Transactions at Merus

In other news, COO Peter B. Silverman sold 34,000 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 82,500 shares of company stock worth $4,586,340. Corporate insiders own 3.70% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.